|
|
| Maladies Infectieuses > Etude de marché sectorielle |
| US State Market Index: Toxins, viruses, and similar substances, including venom |
|
|
|
|
€ 475,00 |
Editeur
: |
BizMiner |
Langue
: |
Anglais |
Date de publication : |
Juillet 2006 |
Taille du document : |
12 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
The Vaccines Market Outlook: Market analysis of future growth and leading players by sector
122 pages | Janvier 2005 |
Business Insights have teamed up with IMS Health to bring you, ‘The Vaccines Market Outlook: Market analysis of future growth and leading players by sector.’ This unique report provides unrivalled ana |
2 443,75 €
|
| |
| |
Stakeholder Insight: Hepatitis in China - Liver Let Die?
310 pages | Décembre 2005 |
IntroductionHepatitis is a major health problem in China, which is home to one third of hepatitis B patients and one quarter of hepatitis C patients globally.
HBV vaccination, together with HBV and |
12 920,00 €
|
| |
| |
Monoclonal Antibody Based Products
489 pages | Octobre 2005 |
This report analyzes the worldwide markets for Monoclonal Antibody Based Products in Millions of US$.
The major product segments analyzed are Therapeutics, and Diagnostics.
The sub product segme |
2 308,00 €
|
| |
| |
Pipeline Insight: Hepatitis C - Small Molecules, Big Revolution
237 pages | Avril 2005 |
IntroductionLess than 50% of chronically infected hepatitis C patients do not benefit from the current standard of care, pegylated interferon plus ribavirin.
In the short-term, the treatment landsc |
9 120,00 €
|
| |
| |
Stakeholder Insight: Hepatitis in China - Liver Let Die?
310 pages | Décembre 2005 |
IntroductionHepatitis is a major health problem in China, which is home to one third of hepatitis B patients and one quarter of hepatitis C patients globally.
HBV vaccination, together with HBV and |
12 920,00 €
|
| |
| |
Commercial Perspectives: HIV - Benchmarking Rapid Antiretroviral Uptake
181 pages | Février 2005 |
IntroductionHistorically, HIV antiretrovirals have differed markedly in their speed of market uptake.
Now, to win market share in an already mature market, newly launched products need not only a s |
9 120,00 €
|
| |
| |
03-054: Immunohistochemistry Market Benchmarking Survey
90 pages | Octobre 2003 |
This report provides an overview of the most commonly used methods and products for tissue/sample preparation and antigen detection to help suppliers understand researchers’ experiences, preferences a |
680,00 €
|
| |
| |
Recommendations for Diagnostic Testing for Hepatitis B
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Stakeholder Insight: Psoriasis - Biologics Impact Treatment Regimes Across the Globe
203 pages | Février 2005 |
IntroductionPsoriasis is a non-life threatening but highly debilitating disease that currently has no cure.
Traditional treatments often either lack efficacy or are effective but have very poor sid |
12 160,00 €
|
| |
| |
Lower Detection Limits of HBV DNA Assays
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| US State Market Index: Toxins, viruses, and similar substances, including venom |
|
|
The metrics in this report cover three year trends in Toxins, viruses, and similar substances, including venom [Manufacturing sector], broken out on a state-by-state basis. Analysis is based on data applied from 8 industry firms. Industry market vitality measures for each state are benchmarked against US averages for the industry, creating easy comparison of state-by-state performance. Industry sales are detailed for both company-wide headquarters data and locally generated sales levels. The report also compares proprietary measures in each state and the US, including failure rates, entrepreneurial activity and new branch development rates in the industry.
|
|
State Market Index Contents
P1-3 Introduction and context for the measures
P4:Industry population and segmentation
P5:Establishment,company and branch failure rates
P6:Total industry sales volume (reported and locally generated)
P7:Average annual reported sales
P8:Average annual generated sales
P9:Startup activity, new branch development,employment concentration
P10:Overall Index
P11:About the data
|
|
|
PPLSEN
|
|
|
|
|
